Selenomethionine

PreclinicalSmall molecule

MMohammed Milhem

Selenomethionine is one of 40 small molecule programs targeting Pembrolizumab. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PembrolizumabActive, not recruiting

PembrolizumabPreclinical

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Pembrolizumab

#DrugCompanyPhaseTrials

Keytruda

Stivarga

3 3

Lenvima

Eisai

Phase 2

11 4

Taxol

Teva

Phase 2

7 5

Paraplatin

AAvyxa

Phase 2

12 6

Lynparza

AstraZeneca

Phase 2

2 7

Cyramza

Eli Lilly

Phase 2

2 8

Trodelvy

Gilead

Phase 2

2 9

Alimta

SShawn Eagle

Phase 2

7 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polyp1 trial

Optimal Selenium for Bowel Polyps (OSCAR)

Completed·UUniversity of Auckland, New Zealand·Phase 1·NCT04952129·56 enrolled

CLE1 trial

SLM + Axitinib for Clear Cell RCC

Completed·MMohammed Milhem·Phase 1·NCT02535533·46 enrolled

Clear Cell Renal Cell Carcinoma1 trial

Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Completed·MMohammed Milhem·Preclinical·NCT05363631·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Selenomethionine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selenomethionine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selenomethionine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mohammed Milhem company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMohammed Milhem

Selenomethionine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polyp1 trial

CLE1 trial

Clear Cell Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News